WEBULL
WebtradeDownload

Does New A1 Protein‑Free Formula Data Change The Bull Case For a2 Milk (NZSE:ATM)?

Simply Wall St · 1d ago
  • The a2 Milk Company recently presented new clinical and preclinical data at NUTRITION 2026 showing its A1 protein‑free infant formula supported normal growth and met U.S. FDA safety criteria through 16 weeks of age.
  • Exploratory findings indicating greater gains in infant length and weight, plus signs of improved protein utilization and gut health, underscore how a2 Milk is using science to differentiate its formula offerings.
  • We’ll now examine how evidence that A1 protein‑free formula supports normal growth and potential digestive advantages may influence a2 Milk’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

a2 Milk Investment Narrative Recap

To own a2 Milk, you need to believe its A1 protein free positioning can keep supporting demand across infant and adult nutrition, while the China business, supply chain transition and premium pricing all hold up. The new NUTRITION 2026 data reinforces the scientific story behind A1 protein free formula but does not obviously change the near term focus on China execution and regulatory risk, or on how quickly Pokeno ramp up affects margins.

The Growth Monitoring Study is the most relevant announcement here, as it directly tests whether A1 protein free infant formula can match conventional formula on growth and safety under U.S. FDA criteria. Those results, plus exploratory signs of better protein utilization and gut health, sit alongside higher FY26 guidance and a growing dividend profile, giving investors more to weigh up around how science backed differentiation might support future formula registration and category positioning.

Yet against this, investors should be aware that...

Read the full narrative on a2 Milk (it's free!)

a2 Milk's narrative projects NZ$2.4 billion revenue and NZ$310.7 million earnings by 2029. This requires 5.9% yearly revenue growth and an earnings increase of about NZ$103 million from NZ$207.3 million today.

Uncover how a2 Milk's forecasts yield a NZ$9.38 fair value, a 14% upside to its current price.

Exploring Other Perspectives

NZSE:ATM 1-Year Stock Price Chart
NZSE:ATM 1-Year Stock Price Chart

If you are weighing this new trial data, remember the lowest analysts were assuming only about 5.6 percent annual revenue growth and NZ$261.9 million earnings by 2029, so their more cautious view on China risk and execution may shift as the science story around A1 protein free formula evolves.

Explore 5 other fair value estimates on a2 Milk - why the stock might be worth just NZ$9.20!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

No Opportunity In a2 Milk?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.